Increase in CD14Superscript+/SuperscriptHLADR

Authors: Fumitaka Arihara Eishiro Mizukoshi Masaaki Kitahara Yoshiko Takata Kuniaki Arai Tatsuya Yamashita Yasunari Nakamoto Shuichi Kaneko

Publish Date: 2013/06/14

Volume: 62, Issue: 8, Pages: 1421-1430

PDF Link

Abstract

Myeloidderived suppressor cells MDSCs are known as key immune regulators in various human malignancies and it is reported that CD14+HLADR−/low MDSCs are increased in hepatocellular carcinoma HCC patients However the host factors that regulate the frequency and the effect on the prognosis of HCC patients are still unclear We investigated these issues and clarified the relationships between a feature of MDSCs and host factors in HCC patients We examined the frequency of MDSCs in 123 HCC patients 30 chronic liver disease patients without HCC and 13 healthy controls by flow cytometric analysis The relationships between the clinical features and the frequency of MDSCs were analyzed In 33 patients who received curative radiofrequency ablation RFA therapy we examined the impact of MDSCs on HCC recurrence The frequency of MDSCs in HCC patients was significantly increased It was correlated with tumor progression but not with the degree of liver fibrosis and inflammation In terms of serum cytokines the concentrations of IL10 IL13 and vascular endothelial growth factor were significantly correlated with the frequency of MDSCs In HCC patients who received curative RFA therapy the frequency of MDSCs after treatment showed various changes and was inversely correlated with recurrencefree survival time The frequency of MDSCs is correlated with tumor progression and this frequency after RFA is inversely correlated with the prognosis of HCC patients Patients with a high frequency of MDSCs after RFA should be closely followed and the inhibition of MDSCs may improve the prognosis of patients

Keywords: